AEMD

Aethlon Medical, Inc.

AEMD · CIK 882291 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20172025
Net Income−$13M
20172025
Operating CF−$8M
20172025
Free Cash Flow−$8M
20172025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2018↕FY 2017↕
Revenue—$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-8.58$-4.86$-0.59—————
EPS (Diluted)$-8.58$-4.86$-0.59—————

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2018↕FY 2017↕
Total Assets$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Assets$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
← Companies